Biome Australia Ltd
ASX:BIO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Biome Australia Ltd
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.
Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.
Record Quarter: Biome Australia reported its most successful quarter ever, with record-breaking sales, positive cash flow, and strong EBITDA.
Revenue & Profitability: Q1 sales were just under $6 million annualized, with $462,000 EBITDA, and seven consecutive quarters of positive EBITDA.
Cash Performance: Cash receipts for Q1 reached $7.14 million, up 84% from the prior period, and the company finished the quarter with around $3 million in cash after repaying working capital lines.
Gross Margin Leadership: Biome maintained a gross margin above 61%, well ahead of market peers.
Growth & Distribution: The company now has products in over 6,000 Australian outlets and is expanding internationally, particularly in Canada, New Zealand, and Ireland.
Vision '27 Progress: Biome remains on track for its Vision '27 goal of at least $75 million in cumulative sales from FY25 to FY27.
Product Innovation: New product lines like Activated Therapeutics were launched, though they contributed immaterial revenue initially.
International Expansion: International sales are growing rapidly, outpacing domestic growth, especially in Canada where market entry barriers are high.
